Background A safe and efficacious vaccine against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …

… T-cell responses peaked at day 14 after a single standard dose of ChAdOx1 nCoV-19 (18–55
years: median 1187 spot-forming cells [SFCs] per million peripheral blood mononuclear …

Background The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large,
diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (…

… The potential role of T cells and interaction between humoral and cellular immunity has
not been evaluated in this study. It is not possible to determine in this study if our results …

Background The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …

Background Assessment of the safety and efficacy of vaccines against the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is …

Background Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract
infection and hospitalization in infants. Nirsevimab is a monoclonal antibody to the RSV fusion …

Pregnant women are a vulnerable group who are needed in clinical research studies to
advance prevention and treatment options for this population. Yet, pregnant women remain …

Background A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of
COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy …

Nirsevimab to Prevent RSV Illness in Infants Nirsevimab, a monoclonal antibody targeting
respiratory syncytial virus, protected against RSV-associated hospitalization and severe …